August 8, 2012

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/08/12 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 1 p.m. ET / 10 a.m. PT on Tuesday, August 14, 2012. Titan will provide the Company's financial results as of June 30, 2012 and an update on the Probuphine program. The call will be hosted by Sunil Bhonsle, President, Katherine Beebe, Ph.D., Executive Vice President and Chief Development Officer, Brian Crowley, Vice President of Finance and Marc Rubin, M.D., Executive Chairman.

Highlights of the second quarter financial results will be included in a press release to be issued prior to the call.

The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com. The call can also be accessed by dialing 888-726-2418 Participant code: 2443039 five minutes prior to the start time. A replay of the call will be available on the Company website approximately two hours after completion of the call and will be archived for two weeks.

About Titan Pharmaceuticals

For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at www.titanpharm.com

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release

CONTACT:

For Investors:

Titan Pharmaceuticals, Inc.
Sunil Bhonsle
650-244-4990
President

For Media:
Pure Communications
Dan Budwick
973-271-6085
dan@purecommunicationsinc.com

Source: Titan Pharmaceuticals, Inc.